PortalPublikationen7-Hydroxy-methotrexate and clinical toxicity following high-...

7-Hydroxy-methotrexate and clinical toxicity following high-dose methotrexate therapy.

Standard

7-Hydroxy-methotrexate and clinical toxicity following high-dose methotrexate therapy. / Erttmann, Rudolf; Bielack, S; Landbeck, G.

in: J CANCER RES CLIN, Jahrgang 109, Nr. 1, 1, 1985, S. 86-88.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Erttmann, R, Bielack, S & Landbeck, G 1985, '7-Hydroxy-methotrexate and clinical toxicity following high-dose methotrexate therapy.', J CANCER RES CLIN, Jg. 109, Nr. 1, 1, S. 86-88. <http://www.ncbi.nlm.nih.gov/pubmed/3855853?dopt=Citation>

APA

Erttmann, R., Bielack, S., & Landbeck, G. (1985). 7-Hydroxy-methotrexate and clinical toxicity following high-dose methotrexate therapy. J CANCER RES CLIN, 109(1), 86-88. [1]. http://www.ncbi.nlm.nih.gov/pubmed/3855853?dopt=Citation

Vancouver

Erttmann R, Bielack S, Landbeck G. 7-Hydroxy-methotrexate and clinical toxicity following high-dose methotrexate therapy. J CANCER RES CLIN. 1985;109(1):86-88. 1.

Bibtex

@article{f53bcdbaad4f4fc7becd28987d3139fd,
title = "7-Hydroxy-methotrexate and clinical toxicity following high-dose methotrexate therapy.",
abstract = "7-Hydroxy-MTX production after consecutive high-dose MTX therapy (12 g/m2) was measured in 7 patients with osteosarcoma by HPLC. 7-Hydroxy-MTX serum values in the last cycle were found to be significantly lower compared with the first high-dose MTX treatment of the adjuvant chemotherapy protocol (COSS 80). Moreover, in another patient highly reduced 7-hydroxy-MTX production was correlated with severe clinical toxicity. As 7-hydroxy-MTX is a 200 fold less potent dihydrofolic acid reductase inhibitor compared with MTX decreased production of the metabolite may lead to enhanced clinical toxicity which may not be predictable monitoring MTX serum levels alone.",
author = "Rudolf Erttmann and S Bielack and G Landbeck",
year = "1985",
language = "Deutsch",
volume = "109",
pages = "86--88",
journal = "J CANCER RES CLIN",
issn = "0171-5216",
publisher = "Springer",
number = "1",

}

RIS

TY - JOUR

T1 - 7-Hydroxy-methotrexate and clinical toxicity following high-dose methotrexate therapy.

AU - Erttmann, Rudolf

AU - Bielack, S

AU - Landbeck, G

PY - 1985

Y1 - 1985

N2 - 7-Hydroxy-MTX production after consecutive high-dose MTX therapy (12 g/m2) was measured in 7 patients with osteosarcoma by HPLC. 7-Hydroxy-MTX serum values in the last cycle were found to be significantly lower compared with the first high-dose MTX treatment of the adjuvant chemotherapy protocol (COSS 80). Moreover, in another patient highly reduced 7-hydroxy-MTX production was correlated with severe clinical toxicity. As 7-hydroxy-MTX is a 200 fold less potent dihydrofolic acid reductase inhibitor compared with MTX decreased production of the metabolite may lead to enhanced clinical toxicity which may not be predictable monitoring MTX serum levels alone.

AB - 7-Hydroxy-MTX production after consecutive high-dose MTX therapy (12 g/m2) was measured in 7 patients with osteosarcoma by HPLC. 7-Hydroxy-MTX serum values in the last cycle were found to be significantly lower compared with the first high-dose MTX treatment of the adjuvant chemotherapy protocol (COSS 80). Moreover, in another patient highly reduced 7-hydroxy-MTX production was correlated with severe clinical toxicity. As 7-hydroxy-MTX is a 200 fold less potent dihydrofolic acid reductase inhibitor compared with MTX decreased production of the metabolite may lead to enhanced clinical toxicity which may not be predictable monitoring MTX serum levels alone.

M3 - SCORING: Zeitschriftenaufsatz

VL - 109

SP - 86

EP - 88

JO - J CANCER RES CLIN

JF - J CANCER RES CLIN

SN - 0171-5216

IS - 1

M1 - 1

ER -